烧伤后早期使用GLP-1受体激动剂与感染、死亡及阿片类药物处方率降低相关
本研究基于TriNetX全球协作网络电子健康记录,将烧伤后30天内接受GLP-1受体激动剂(GLP-1 RAs)治疗的患者与倾向匹配的未使用者各3231例进行比较。结果显示,GLP-1 RAs组在烧伤后90天时软组织感染、阿片类药物处方、再入院和死亡率均显著降低(均p<0.05),1年时阿片处方、再入院和死亡率仍较低,但软组织感染率未达统计学显著性;两时间点伤口裂开、增生性瘢痕或挛缩形成均无显著差异。
要点
- 烧伤后30天内使用GLP-1 RAs与90天感染、阿片处方、再入院及死亡率降低相关
- 1年时阿片处方、再入院和死亡率降低仍持续,感染率未达显著
- 伤口裂开、增生性瘢痕及挛缩形成无显著差异
核心结论
- 近期烧伤后使用GLP-1 RAs与感染、阿片类药物处方、再入院和死亡率降低相关,其在烧伤救治中的价值值得进一步研究。
研究设计与样本
- 回顾性队列研究,查询TriNetX全球协作网络电子健康记录,治疗组为烧伤后30天内接受GLP-1 RAs者,经倾向匹配与未使用者比较,每组3231例。
主要发现
- 烧伤后90天,GLP-1 RAs组软组织感染、阿片类药物处方、再入院和死亡率均显著低于对照组(均p<0.05)。
- 烧伤后1年,阿片类药物处方、再入院和死亡率降低仍持续(均p<0.05),软组织感染率数值更低但未达统计学显著性。
- 两时间点伤口裂开、增生性瘢痕形成或挛缩形成均无显著差异。
临床怎么用
- 对合并糖尿病或肥胖的烧伤患者,可关注GLP-1 RAs使用史并评估其与感染、阿片使用及再入院风险的关联。
局限性
- 原文未明确报告局限性内容,需结合研究设计类型理解其因果推断限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely prescribed for glycemic control and weight loss. In addition, these medications have been associated with anti-inflammatory activity, modulation of wound healing, and reduction of substance use disorders. Therefore, GLP-1 RAs may have therapeutic benefits in burn care. This study investigates whether early administration of GLP-1 RAs after burn injury is associated with clinical outcomes. METHODS: The Global Collaborative Network was queried in TriNetX, a database of electronic health records. The treatment group included burn patients who received GLP-1 RAs within 30 days of injury. This group was propensity matched with patients who did not receive GLP-1 RAs. Patients were matched by demographics, comorbidities, and burn characteristics. Outcomes at 90 days and 1 year following burn injury were compared, with statistical significance defined as p < 0.05. RESULTS: Following matching, each group was composed of 3231 patients. At 90 days post-burn, the GLP-1 RA group had significantly lower rates of soft tissue infection, opioid prescriptions, readmission, and mortality (all p < 0.05). At 1 year post-burn, lower rates of opioid prescriptions, readmission, and mortality persisted (all p < 0.05), while soft tissue infection rates remained numerically lower but did not reach statistical significance. No significant differences were observed for wound disruption, hypertrophic scar formation, or contracture formation at either time point. CONCLUSIONS: GLP-1 RAs after recent burn injury were associated with lower risk of infection, opioid prescriptions, readmission, and mortality. Their utility in burn care is promising, and additional research is needed.
引用
- Dao MQ, Kim AY, Wang S, et al. Glucagon-like peptide-1 receptor agonists after recent burn injury are associated with lower rates of infection, mortality, and opioid prescriptions. Burns. 2025. PMID: 41581262. doi:10.1016/j.burns.2025.107848
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。